Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid
28 juin 2016 16h05 HE
|
Esperion Therapeutics, Inc.
On track to initiate global pivotal Phase 3 studies and CVOT in the fourth quarter Aligned with global regulatory authorities on a consistent definition of statin intolerance Conference...
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
04 mai 2016 08h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...
Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
08 mars 2016 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 08, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...
Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results
25 févr. 2016 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...
Esperion Therapeutics to Present at the 2016 RBC Capital Markets Global Healthcare Conference
16 févr. 2016 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...
Esperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study
13 janv. 2016 08h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...
Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy
12 janv. 2016 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...
Esperion Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
06 janv. 2016 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...